A radiation-sensitive composition containing a resist compound having a high sensitivity, a high resolution, a high etching resistance, and a low outgas which forms a resist pattern with a good shape is described.

A radiation-sensitive composition containing a resist compound having a high sensitivity, a high resolution, a high etching resistance, and a low outgas which forms a resist pattern with a good shape is described.

The present invention relates to therapeutic applications of aniline derivatives of formula (I), for example in treating glaucoma: Formula (I), R1a represents H, an halogen, a (C.sub.1-C.sub.6)alkyl or a CN; R1b represents H, an halogen or a (C.sub.1-C.sub.6)alkyl; R1c represents H or a (C.sub.1-C.sub.6)alkyl; R2 represents H, an halogen, an OH, an O(C.sub.1-C.sub.6)alkyl or (C.sub.1-C.sub.6)alkyl; R3 represents H, an halogen, a (C.sub.1-C.sub.6)alkyl, an OH, an O(C.sub.1-C.sub.6)alkyl, a CONH.sub.2 or CN; R4 represents H, an halogen or a (C.sub.1-C.sub.6)alkyl; R5 represents H or F: R7 represents H or F; R8 represents H or F; R9 represents H or (C.sub.1-C.sub.6)alkyl, or one of its enantiomers. ##STR00001##

The present invention relates to therapeutic applications of aniline derivatives of formula (I), for example in treating glaucoma: Formula (I), R1a represents H, an halogen, a (C.sub.1-C.sub.6)alkyl or a CN; R1b represents H, an halogen or a (C.sub.1-C.sub.6)alkyl; R1c represents H or a (C.sub.1-C.sub.6)alkyl; R2 represents H, an halogen, an OH, an O(C.sub.1-C.sub.6)alkyl or (C.sub.1-C.sub.6)alkyl; R3 represents H, an halogen, a (C.sub.1-C.sub.6)alkyl, an OH, an O(C.sub.1-C.sub.6)alkyl, a CONH.sub.2 or CN; R4 represents H, an halogen or a (C.sub.1-C.sub.6)alkyl; R5 represents H or F: R7 represents H or F; R8 represents H or F; R9 represents H or (C.sub.1-C.sub.6)alkyl, or one of its enantiomers. ##STR00001##

An object of the present invention is to provide a method for producing 4,4-dihydroxybiphenyl-3,3-dicarboxylic acid in a high yield. Disclosed is a method for producing 4,4-dihydroxybiphenyl-3,3-dicarboxylic acid represented by formula (2),

##STR00001## the method comprising a step of reacting a 4,4-dihydroxybiphenyl dialkali metal salt represented by formula (1),

##STR00002## wherein M represents sodium, lithium, rubidium, or cesium, with carbon dioxide in 2-ethylhexanol.

An object of the present invention is to provide a method for producing 4,4-dihydroxybiphenyl-3,3-dicarboxylic acid in a high yield. Disclosed is a method for producing 4,4-dihydroxybiphenyl-3,3-dicarboxylic acid represented by formula (2),

##STR00001## the method comprising a step of reacting a 4,4-dihydroxybiphenyl dialkali metal salt represented by formula (1),

##STR00002## wherein M represents sodium, lithium, rubidium, or cesium, with carbon dioxide in 2-ethylhexanol.

The present invention relates to compositions comprising a cannabidolic acid cocrystal. In particular, the cannabidiolic acid cocrystals include a cannabidiolic acid L-phenylalanine cocrystal, a cannabidiolic acid vanillin cocrystal, a cannabidiolic acid betaine cocrystal, a cannabidiolic acid ethyl maltol cocrystal, a cannabidiolic acid L-proline cocrystal and a cannabidiolic acid D-proline cocrystal. The present invention also relates to compositions, particularly pharmaceutical compositions comprising a cannabidiolic acid cocrystal and a pharmaceutically acceptable carrier. The present invention further relates to methods to treat a disease, disorder or condition in a patient by administering to the patient a therapeutically effective amount of cannabidiolic acid cocrystal or a pharmaceutical composition comprising a therapeutically effective amount of cannabidiolic acid cocrystal.

The present invention relates to compositions comprising a cannabidolic acid cocrystal. In particular, the cannabidiolic acid cocrystals include a cannabidiolic acid L-phenylalanine cocrystal, a cannabidiolic acid vanillin cocrystal, a cannabidiolic acid betaine cocrystal, a cannabidiolic acid ethyl maltol cocrystal, a cannabidiolic acid L-proline cocrystal and a cannabidiolic acid D-proline cocrystal. The present invention also relates to compositions, particularly pharmaceutical compositions comprising a cannabidiolic acid cocrystal and a pharmaceutically acceptable carrier. The present invention further relates to methods to treat a disease, disorder or condition in a patient by administering to the patient a therapeutically effective amount of cannabidiolic acid cocrystal or a pharmaceutical composition comprising a therapeutically effective amount of cannabidiolic acid cocrystal.

The present invention relates to compositions comprising a cannabidolic acid cocrystal. In particular, the cannabidiolic acid cocrystals include a cannabidiolic acid L-phenylalanine cocrystal, a cannabidiolic acid vanillin cocrystal, a cannabidiolic acid betaine cocrystal, a cannabidiolic acid ethyl maltol cocrystal, a cannabidiolic acid L-proline cocrystal and a cannabidiolic acid D-proline cocrystal. The present invention also relates to compositions, particularly pharmaceutical compositions comprising a cannabidiolic acid cocrystal and a pharmaceutically acceptable carrier. The present invention further relates to methods to treat a disease, disorder or condition in a patient by administering to the patient a therapeutically effective amount of cannabidiolic acid cocrystal or a pharmaceutical composition comprising a therapeutically effective amount of cannabidiolic acid cocrystal.

The present invention relates to compositions comprising a cannabidolic acid cocrystal. In particular, the cannabidiolic acid cocrystals include a cannabidiolic acid L-phenylalanine cocrystal, a cannabidiolic acid vanillin cocrystal, a cannabidiolic acid betaine cocrystal, a cannabidiolic acid ethyl maltol cocrystal, a cannabidiolic acid L-proline cocrystal and a cannabidiolic acid D-proline cocrystal. The present invention also relates to compositions, particularly pharmaceutical compositions comprising a cannabidiolic acid cocrystal and a pharmaceutically acceptable carrier. The present invention further relates to methods to treat a disease, disorder or condition in a patient by administering to the patient a therapeutically effective amount of cannabidiolic acid cocrystal or a pharmaceutical composition comprising a therapeutically effective amount of cannabidiolic acid cocrystal.